Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Roberto Méndez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9952-3255; OpenAlex author ID A5101700826. Sources: OpenAlex.

Their work

Papers
3 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper

Papers 3

  1. Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC. First author DOI 10.1080/19490976.2022.2096328↗
  2. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Co-author DOI 10.1093/carcin/bgz116↗
  3. Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma. First author DOI 10.1186/s12934-020-01330-3↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sulagna Banerjee · 3 shared papers, 2020–2022 · strength 0.41
  2. Kousik Kesh · 3 shared papers, 2020–2022 · strength 0.41
  3. Santanu Banerjee · 3 shared papers, 2020–2022 · strength 0.41
  4. Nipun B. Merchant · 2 shared papers, 2020–2022 · strength 0.26
  5. Vineet Kumar Gupta · 1 shared paper, 2022 · strength 0.15
  6. Beatriz Mateo-Victoriano · 1 shared paper, 2022 · strength 0.15
  7. Jashodeep Datta · 1 shared paper, 2022 · strength 0.15
  8. Florencia M. McAllister · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.